The deal, announced on Thursday, extricates Roche from ownership ties to a major competitor with strategic vetoing power, though it has kept a passive role in the face of powerful Roche family shareholders.
Roche can afford the deal without cutting back on research and development spending, and acquisitions, Franz told Swiss newspaper Finanz und Wirtschaft.
Bridge financing will be used initially to pay Novartis, and then Roche would refinance the debt through longer-term instruments such as bonds, he said.
“Our net debt is almost zero. It is very important that we can raise the substantial debt without compromising operational and strategic flexibility with regard to our core business,” Franz said.
“We can continue our focus on research and development, we can continue in-licensing and acquisitions as we have done in the past years. We are not losing any freedom as a result of this transaction. Quite the opposite.”
Franz said he saw the new situation, with the repurchased shares being eliminated, as helping Roche